It has been reported that multiple insider activity took place at Verrica Pharmaceuticals Inc. (VRCA). 10% Owner Davidson Matt sold 4,110 shares for $2,708,687 in transaction occurred on 2019/06/03. After making this transaction, 10% Owner owns a direct stake of -3 shares, worth $19,421,286, as per the last closing price. On 2019/05/29 Davidson Matt, 10% Owner at VRCA, dumped 2,100 shares at an average price of $8.41 per share. The selling total is valued at $19,450,754.
10% Owner, Davidson Matt had divested 2,422 shares for $2,714,897 through a trade on 2019/05/23. Following this activity, the insider holds -19 shares worth $19,465,811 as of recent close.
Fidelity Select Portfolios – Biotechnology revealed as top hedge fund owner in Verrica Pharmaceuticals Inc. (VRCA) with a stake of over 621,800 VRCA shares as of March 30, with a market value of approx. $6.72M as of today. The second largest holder, Buffalo Small Cap Fund, with 326390 shares which equates to $3.53M worth of the stock. At third is Vanguard Total Stock Market Index Fund, which stood pat with 247806 shares, a 2.19% position in Verrica Pharmaceuticals Inc., worth $4.03M. The insider holding in stood at 43.6% while institutions hold 34.9%.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) rose 0.56% in recent trade and currently has a stock-market value of $184.34M. The shares finished at $7.17, after trading as low as $6.85 earlier in the session. It hit an intraday high Monday at $7.52. Trading activity significantly improved as the volume at ready counter increased to 52,917 shares versus 34,310 in average daily trading volume over the past 20 days. So far this year, the volume has averaged about 52,200 shares. Now the market price is down 0% on the year and down -12.02% YTD.
VRCA stock’s 50 day simple moving average (SMA 50) price is $9.72 and its 200-day simple moving average (SMA 200) price is $12.11. The company’s stock currently has a total float of 12.18M shares. Its weekly volatility is hovering around 8.79% and felt 7.69% volatility in price over a month. On the upside, the share price will test short term resistance at around $7.51. On a downside, the stock is likely to find some support, which begins at $6.84. The failure to get near-term support could push it to $6.51.
It had seen a new analyst call from H.C. Wainwright, which initiated the stock at Buy on February 21.
Also, it is trading at rather expensive levels at just over 2.15x price/book and 0x price/sales. VRCA’s ROE is -28.4%, which is also considerably worse than the industry’s ROE of 13.7%. It’s also very liquid in the near term, with a current ratio of 27.7. The stock has a debt/capital of 0.
VRCA last reported earnings that receded expectations. The company raked in -$0.3 per share, -96.93% change on the same period last year. That was worse than consensus for -$0.27. For this quarter, Wall Street analysts forecast revenue in a range of $0 to $0, which should be compared with $0 generated last year. EPS is seen in a range of -$0.34 to -$0.26, against the 0 reported a year ago.